Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Multiple Myeloma: Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

Research Question:
Will adding selinexor to other treatment combinations have any effect on your cancer?

Basic Study Information

Purpose:
This is an open-label study, which means that both you and your study doctor will know how much selinexor and the names of other medications you are taking. You, and all other patients in this study, will take the study drug selinexor, plus dexamethasone and either pomalidomide, bortezomib, lenalidomide, or daratumumab. The treatment period consists of blocks of time called cycles. The number of treatment cycles you receive will depend on how well you are doing on the treatment and how well your cancer responds to it. This study includes four different treatment combinations: • Selinexor, dexamethasone and pomalidomide (abbreviated as SPd) • Selinexor, dexamethasone and bortezomib (abbreviated as SVd) • Selinexor, dexamethasone and lenalidomide (abbreviated as SRd) • Selinexor, dexamethasone, daratumumab (abbreviated SDd)

Location: Cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02343042?term=KCP-330-017&rank=1
Study Reference #: IMMY-16088

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: katherine Nedrow
Phone: (585) 275-3893
Email: Katherine_Nedrow@URMC.Rochester.edu

Additional Study Details

Return to Search